Milestone Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Milestone Pharmaceuticals has a total shareholder equity of $24.0M and total debt of $52.4M, which brings its debt-to-equity ratio to 218.4%. Its total assets and total liabilities are $82.7M and $58.7M respectively.
Key information
218.4%
Debt to equity ratio
US$52.43m
Debt
Interest coverage ratio | n/a |
Cash | US$76.42m |
Equity | US$24.01m |
Total liabilities | US$58.69m |
Total assets | US$82.71m |
Recent financial health updates
Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?
Nov 06Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?
Sep 13We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate
Mar 07We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate
Oct 15We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth
Jun 24We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely
Feb 25Recent updates
Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?
Nov 06Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely
Jun 07Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?
Sep 13We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate
Mar 07We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate
Oct 15We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth
Jun 24We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely
Feb 25We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow
Aug 25Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth
Apr 02What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition
Jan 15First patient enrolled in Milestone Pharmaceuticals' late-stage study of etripamil in PSVT
Nov 18Milestone Pharmaceuticals EPS beats by $0.09
Nov 13Financial Position Analysis
Short Term Liabilities: MIST's short term assets ($81.0M) exceed its short term liabilities ($5.3M).
Long Term Liabilities: MIST's short term assets ($81.0M) exceed its long term liabilities ($53.4M).
Debt to Equity History and Analysis
Debt Level: MIST has more cash than its total debt.
Reducing Debt: MIST's debt to equity ratio has increased from 0% to 218.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MIST has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MIST has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 1.3% each year.
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/31 08:20 |
End of Day Share Price | 2025/01/31 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Milestone Pharmaceuticals Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Patrick Trucchio | H.C. Wainwright & Co. |
Christopher Howerton | Jefferies LLC |
Yuchen Ding | Jefferies LLC |